<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01029613</url>
  </required_header>
  <id_info>
    <org_study_id>WRAP</org_study_id>
    <nct_id>NCT01029613</nct_id>
  </id_info>
  <brief_title>Adalimumab in Rheumatoid Arthritis. An Investigation of Wholebody MRI, Conventional MRI, CT and Circulating Biomarkers</brief_title>
  <official_title>Adalimumab in Rheumatoid Arthritis. An Investigation of Changes in Disease Activity and Course of Joint Destruction by Use of 3 Tesla Whole-Body MRI, Dedicated 3 Tesla MRI and CT of the Hand, and Soluble Biomarkers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Glostrup University Hospital, Copenhagen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Glostrup University Hospital, Copenhagen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Adalimumab in rheumatoid arthritis. An investigation of changes in disease activity and
      course of joint destruction by use of 3 Tesla Whole-Body MRI, dedicated 3 Tesla MRI and CT of
      the hand, and soluble biomarkers. Furthermore to compare ultrasound examination with
      wholebody MRI etc.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>EULAR response criteria</measure>
    <time_frame>16 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of joints with inflammation on MRI</measure>
    <time_frame>16 and 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Erosions on X-rays and CT</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers</measure>
    <time_frame>16 and 52 weeks</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">40</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Rheumatoid arthritis</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adalimumab</intervention_name>
    <description>sc. inj. Humira 40 mg every other week from week 0 to 52</description>
    <arm_group_label>Rheumatoid arthritis</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with rheumatoid arthritis according to the ACR criteria (1987) with high disease
        activity starting TNF-alpha inhibitor
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years old and &lt; 85 years old

          -  RA in accordance with American College of Rheumatology 1987 criteria

          -  Moderate or highly active RA defined as DAS28 &gt; 3,2 (CRP based)

          -  Clinical indication for TNF-α inhibitor treatment by the treating physician

          -  No contraindications for TNF-α inhibitor treatment

          -  No contraindications for MRI

          -  Serum creatinine in normal range

          -  Sufficient contraception for fertile women

          -  Capable of giving informed consent

          -  Capable of complying with the examination program of the protocol

        Exclusion Criteria:

          -  Other DMARDs than MTX from less than 4 weeks before inclusion and throughout the study
             period

          -  Cyclophosphamide, Chlorambucil or other alkylating agents from less than 4 weeks
             before inclusion and throughout the study period

          -  Intramuscular or intravenous injection of glucocorticoid from less than 4 weeks before
             inclusion and throughout the study period

          -  Pregnancy wish, pregnancy or breast-feeding

          -  Contraindications for TNF-α inhibitor treatment

          -  Contraindications for MRI

          -  Known recent drug or alcohol abuse

          -  Failure to provide written consent

          -  Incapable of complying with the examination program for physical or mental reasons
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mikkel Østergaard, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dep. of Rheumatology, Glostrup Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Susanne J Pedersen, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Dep. of Rheumatology, Glostrup Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dep. of medicine, Herlev Hospital</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dep. of Radiology, Herlev Hospital</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dep. of Rheumatology, Frederiksberg and Bispebjerg Hospitals</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dep. of Rheumatology, Gentofte Hospital</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dep. of Rheumatology, Glostrup Hospital</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dep. of Rheumatologym Glostrup Hospital</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dep. of Rheumatology, Helsingør Hospital</name>
      <address>
        <city>Hørsholm</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dep. of Rheumatology, Køge Hospital</name>
      <address>
        <city>Køge</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 9, 2009</study_first_submitted>
  <study_first_submitted_qc>December 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 10, 2009</study_first_posted>
  <last_update_submitted>August 18, 2015</last_update_submitted>
  <last_update_submitted_qc>August 18, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 19, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Glostrup University Hospital, Copenhagen</investigator_affiliation>
    <investigator_full_name>MOstergaard</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adalimumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

